Quality of Life in elderly patients with cancer by Di Maio, Massimo & Perrone, Francesco
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
Health and Quality of Life Outcomes
Open Access Review
Quality of Life in elderly patients with cancer
Massimo Di Maio and Francesco Perrone*
Address: Clinical Trials Unit, National Cancer Institute, 80131 Naples, Italy
Email: Massimo Di Maio - dimaiomax@libero.it; Francesco Perrone* - fr.perrone@agora.it
* Corresponding author    
Abstract
The incidence of most types of cancers is age-dependent and the progressive ageing is rapidly
increasing the number of elderly people who need treatment for cancer. Elderly patients present
peculiar characteristics that make the choice of the correct treatment more difficult and these
patients are often undertreated. Moreover, elderly patients are largely underrepresented in cancer
treatment trials, and this makes the experimental evidence on this topic even weaker. Health-
related Quality of Life (QOL) has been considered as one of the hard end-points for clinical cancer
research, and treatment of elderly cancer patients represents a typical situation where its
assessment can be particularly useful, because the expected toxicity of treatment could be relevant
in the discussion of the treatment choice. However, QOL assessment in the elderly is complicated
by several unresolved methodological problems (higher frequency of illiteracy, worse compliance
with the questionnaires, concomitant diseases, use of instruments not validated in the aged
population). Conduct of clinical trials dedicated to elderly patients is now encouraged but there are
few published studies. Advanced non-small-cell lung cancer is one of the fields with the largest
amount of research on QOL in elderly patients. The ELVIS study demonstrated the efficacy of
single-agent chemotherapy, both in terms of QOL and of survival. The MILES study, in which
combination chemotherapy was not superior than single agents, showed that baseline QOL is a
strong prognostic indicator in these patients. QOL of patients with breast cancer has been another
important field in clinical research over the last decades, and interest on this topic in elderly
patients is growing, from loco-regional to palliative treatment.
In conclusion, some steps have been done in clinical cancer research dedicated to elderly patients,
and the role of QOL assessment in this setting is important. However, many methodological
problems must be resolved, in order to obtain reliable and useful results. A QOL assessment could
also be useful for elderly patients in clinical practice, where it could improve patient-clinician
communication: a wider application of properly selected instruments should be recommended.
Review
Elderly patients and cancer between clinical practice and 
research
If current incidence rates will not decrease, in the next fifty
years the number of people diagnosed with cancer is
expected to double, solely due to the progressive ageing of
the population [1]. Ageing is rapidly affecting the median
age of all Western populations, mostly due to the reduc-
tion in birthrate, coupled with the increased life expect-
ancy (figure 1). This demographic phenomenon is rapidly
increasing the number of people who are diagnosed and
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treated for cancer, because the incidence of most types of
cancers is age-dependent and the risk of developing a
tumor is progressively higher with increasing age [2].
Elderly patients present peculiar characteristics [3,4] that
make the choice of the correct treatment more difficult,
often exposing these patients to the risk of being under-
treated [5]. Although chronological age is not necessarily
equivalent to biological age, ageing determines physiolog-
ical changes in organ functions and pharmacokinetics.
Furthermore, concomitant diseases are very frequent, sig-
nificantly affecting the functional status and the general
health condition, in addition to tumor symptoms. There-
fore, a correct approach to elderly people with cancer
should not leave out a comprehensive geriatric assess-
ment, in the attempt to better predict the prognosis of the
patient and the risks associated with specific treatments
[6].
Despite the universal recognition of the importance of
clinical trials to inform clinical practice and to guide ther-
apeutic decisions, it has been repeatedly reported that eld-
erly patients are largely underrepresented in cancer
treatment trials [7–9]. The first major survey was pub-
lished in 1999 by Hutchins et al [7]. They analyzed 164
clinical trials conducted by the South West Oncology
Group, for a total of 16.396 patients, comparing the pro-
portion of elderly patients enrolled in clinical trials with
the proportion of elderly people diagnosed with cancer in
the general population. They reported that 25% of the
trial population was over 65, compared with 63% of the
overall cancer patient population. Another similar survey
Percentage distribution of the population in selected age groups, in 2000 and 2050 Figure 1
Percentage distribution of the population in selected age groups, in 2000 and 2050. Data from: Population Division of the 
Department of Economic and Social Affairs of the United Nations Secretariat (2003). World Population Prospects: The 2002 Revi-
sion. Highlights. New York: United Nations.
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has been recently presented at the 39th Annual Meeting of
the American Society of Clinical Oncology in Chicago [9].
Authors analyzed data from 29,350 patients enrolled in
trials conducted over seven years (from 1995 to 2002)
dealing with treatments for six different types of cancer.
Similarly to the other surveys, the percentage of cancers of
each type that were diagnosed in older patients in the gen-
eral population was compared with the percentage of eld-
erly patients enrolled in clinical trials for each cancer. A
great disparity between percentages of elderly patients in
the general population and in clinical trials was found for
pancreatic cancer (71% vs 33%), leukemia (54% vs 24%),
colorectal cancer (70% vs 41%), lung cancer (67% vs
35%), with smaller but yet statistically significant dispari-
ties for ovarian (44% vs 31%) and breast cancers (49% vs
45%). It is worth to be noted, although predictable, that
underrepresentation was particularly notable for patients
older than 75 years.
This phenomenon can significantly affect the generaliza-
bility of trials'results, that largely depend upon whether
subjects enrolled in clinical trials are fully representative
of the entire spectrum of patients suffering from that
disease.
The role of Quality of Life assessment in cancer
Health-related Quality of Life (QOL) has been recom-
mended as one of the hard end-points for clinical cancer
research [10]. Use of QOL instruments may be particu-
larly appropriate when treatments are not expected to
achieve significant advantages in terms of overall survival
(e.g. advanced non-small-cell lung cancer): in the case of
metastatic cancer, guidelines from the American Society of
Clinical Oncology state that a treatment can be recom-
mended even without an improvement in survival, if it
demonstrates an improvement in terms of quality of life
[10]. QOL assessment can also be useful when the
expected toxicity of treatment (either due to treatment
itself or to characteristics of patients) could be so relevant
to put into discussion the treatment choice. Treatment of
elderly cancer patients represents a typical such case.
In addition, it should not be forgotten that patients might
have a preference for a treatment potentially able to
improve their quality of life rather than their survival [11]:
when asked to choose between supportive care and chem-
otherapy, only 22% of the patients chose chemotherapy
for a hypothesized survival benefit of 3 months. Con-
versely, 68% patients chose chemotherapy if it substan-
tially reduced symptoms, even if no significant effect on
survival was expected.
Methodological issues of Quality of Life assessment in the 
elderly
A good quality of life should be a primary goal in the treat-
ment of elderly patients with cancer, but to date very few
studies have specifically focused on this topic [12,13].
Thus, assessment of health-related QOL in elderly patients
with cancer remains a controversial area of research, with
specific implications, both in measuring and in evaluating
the results (table 1). This may have discouraged the plan-
ning of clinical trials in this setting [13]. All the methodo-
logical problems related to QOL evaluation are somewhat
magnified in the elderly. Aged patients may suffer from a
higher proportion of illiteracy, and this may translate into
increased difficulty to correctly understand the question-
naires administered [14]. Furthermore, the real impact of
cancer symptoms and the harms and benefits of specific
treatments in terms of quality of life may be confounded
by the comorbidities, that are typically frequent and clin-
ically significant in this category of patients [4]. Elderly
patients have shown lower compliance to QOL question-
naires when compared to younger counterparts [15], and
this creates the problem of a correct interpretation of data,
given that the pattern of missing data is most likely non-
random. This problem can be particularly evident for
tumors characterized by a poor short-term prognosis and
a rapid deterioration of patients'conditions. It has been
shown, in elderly patients affected by advanced non-
small-cell lung cancer, that the baseline scores are worse
for the patients who are going to fill in fewer question-
naires, as compared to the patients who fill in all the
planned QOL assessments [16]. These data clearly suggest
that the missing data would probably be the worst ones.
Of course, this can lead to biased estimation of QOL in
clinical trials, if missing data are not equally distributed
among study arms.
Table 1: Methodological problems of Quality of Life (QOL) evaluation in the elderly
• Higher proportion of illiteracy as compared to younger patients
• Presence of cognitive disorders with difficulty to understand QOL questionnaires
• Presence of comorbidities potentially confusing the real impact of cancer and treatment on QOL
• Use of QOL instruments needs validation in elderly patients
• Analysis of QOL data from subgroups of elderly patients enrolled in clinical trials without upper age limit suffer from selection bias.Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/44
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As for clinical practice, a QOL instrument can be a useful
clinical tool in conducting a thorough medical assessment
[17]. This can be particularly true in the care of the older
patient with cancer.
When using QOL instruments in in an aged cancer popu-
lation, validity and reliability in this category of patients
of instruments not specifically designed for elderly should
be demonstrated [18]. It cannot be assumed that a QOL
instrument validated in younger individuals is equally
appropriate for use in elderly patients, who are likely to
have different values and perceptions when compared
with younger patients. Some attempts have been made to
develop and validate QOL instruments specifically devel-
oped for the geriatric population [19], or to validate
widely used instruments in elderly patients. For example,
one of the most widely used QOL instruments, the Func-
tional Assessment of Cancer Therapy General Scale
(FACT-G), has been recently validated in elderly cancer
patients [20]. FACT-G total score and subscores were com-
pared with the mixed aged cancer patient normative
group of Cella et al. [21]. Authors'conclusions were that
FACT-G proved a valid and reliable instrument, not
biased by patients'age. Higher scores on the FACT-G ques-
tionnaire were reported by subjects with higher Eastern
Cooperative Oncology Group Performance Status (PS),
that is expression of the physician's assessment of the
patient's conditions. For example, subjects with PS0 had a
mean total FACT-G score of 87.9, compared to a mean
score of 59.0 for patients with PS3. Other QOL instru-
ments, the SF-20 and the Rotterdam symptom checklist,
have been validated in older patients affected by aggres-
sive non-Hodgkin's lymphoma [22].
In the next section, evidence regarding QOL in elderly
patients affected by two of the most frequent types of
tumors, non-small-cell lung cancer and breast cancer, are
reviewed.
Quality of life in elderly patients with non-small-cell lung 
cancer
The majority of patients affected by lung cancer are unfor-
tunately diagnosed at advanced stage, when palliative
treatment is the only therapeutic option. Standard treat-
ments available to date, consisting of chemotherapy with
cytotoxic drugs, are far from being satisfactory, achieving
very small survival benefits encumbered by a not negligi-
ble toxicity. Therefore, non-small-cell lung cancer
(NSCLC) can be considered paradigmatic of a large field
of oncologic research in which particular attention should
be paid to QOL assessment, especially in elderly patients
[23].
The ELVIS study (Elderly Lung cancer Vinorelbine Italian
Study), a randomized phase III trial conducted by our
cooperative group, was published in 1999 [16]. This trial
represented a very important step in this field, because it
was specifically designed for elderly patients. Patients
older than 70 years affected by advanced NSCLC were ran-
domized to receive best supportive care alone or best sup-
portive care plus chemotherapy (single-agent vinorelbine
at the dose of 30 mg/m2, days 1 and 8 every three weeks
for a maximum of six cycles). The main end-point of the
study was QOL and for its assessment the European
Organization for Research and Treatment of Cancer
(EORTC) core questionnaire (QLQ-C30) and lung-can-
cer-specific module (QLQ-LC13) were used. The trial
began in April 1996. During the conduct of the study,
however, investigators, although blinded to the results,
were increasingly reluctant to randomize patients,
because they could have been assigned to a control arm
without chemotherapy. Furthermore, an increasing
number of patients refused to participate in the study,
explicitly asking for chemotherapy. Accrual rate had con-
sequently dwindled from eleven to five patients per
month, and the enrollment of the study was interrupted
in November 1997, before reaching the planned sample-
size.
The effect of vinorelbine on QOL was evaluated by fitting
a linear mixed model for each EORTC scale, taking into
account all the QOL assessments (baseline; before each
course of chemotherapy in the vinorelbine arm and
before each follow-up visit in the control arm). QOL
results showed several significant differences between the
two arms, related to the side effects of chemotherapy and
to its benefits in terms of tumor symptoms and function-
ing scales. Consistent with the expected toxicity profile of
vinorelbine, patients receiving chemotherapy reported
worse scores on the scales relating to nausea and vomit-
ing, constipation, peripheral neuropathy and hair loss.
However, patients treated in the vinorelbine arm scored
clearly better than controls on many subscales: global
health status/quality of life, four functioning scales (role,
cognitive, social and physical functioning), fatigue, pain,
dyspnea, cough, hemoptysis, pain in the chest and shoul-
der, pain in other sites and need for analgesia (figure 2).
With 161 patients analyzed, those assigned to vinorelbine
plus best supportive care had a significantly longer sur-
vival (28 weeks vs 21 weeks, log-rank test p = 0.03) and
had greater chance to be alive at six months (55% vs 41%)
and at one year (32% vs 14%) than those who did not
receive chemotherapy. When adjusted by tumor stage and
patient's performance status, the relative risk of death in
the group treated with chemotherapy was 0.65 (95% CI:
0.45–0.93; p = 0.02).
The results of the ELVIS trial have demonstrated the ben-
efit of single agent chemotherapy with vinorelbine in eld-
erly patients affected by NSCLC. In order to test if theHealth and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/44
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Estimated effect of vinorelbine on Quality of Life of elderly patients with advanced non-small-cell lung cancer Figure 2
Estimated effect of vinorelbine on Quality of Life of elderly patients with advanced non-small-cell lung cancer.
WORSENING       IMPROVEMENT
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polichemotherapy could have been more effective than
single agents in the treatment of these patients, we
designed and conducted, within the same cooperative
group, another phase III trial, the MILES trial [24], dedi-
cated to the same patients'population of the ELVIS study.
The combination of vinorelbine (25 mg/m2) plus gemcit-
abine (1000 mg/m2) was compared to single-agent vinor-
elbine (30 mg/m2) or gemcitabine (1200 mg/m2). All
drugs were given on day 1 and 8 every three weeks, for a
maximum of six cycles. Although overall survival was the
primary end-point of the study, a QOL assessment was
planned, using the same instruments of the ELVIS trial
(EORTC QLQ-C30 and LC13). At the end of the enrol-
ment, 698 patients were analyzed: median age was 74
years, and 275 patients (39%) were 75 years or older.
Combination chemotherapy proved slightly more toxic
than monochemotherapy, but unfortunately did not
show any advantage as compared with each single drug.
EORTC questionnaires at the end of the third cycle of
chemotherapy were completed by 346 of the 585 patients
(59%) who had completed the questionnaires at baseline.
There were no significant differences in functional and
symptoms scales between patients assigned to the combi-
nation and those assigned to single-drug treatments. Only
hair loss, as estimated by the patients, was significantly
worse with vinorelbine plus gemcitabine than with gem-
citabine (P = 0.03).
Interestingly, a secondary analysis of the MILES study [25]
has evaluated the prognostic role of baseline QOL
(EORTC C30 global QOL score – items 29 and 30) in the
elderly patients, together with the prognostic role of geri-
atric functional status (ADL – activities of daily living –
and IADL – instrumental activities of daily living). ADL
status, IADL status and baseline QOL score were added to
a predefined multivariable model: ADL status was not an
independent prognostic factor for survival, IADL status
showed independent prognostic role only for worst
scores, while baseline QOL score was a strong and inde-
pendent prognostic factor for survival, even when control-
ling for performance status, histotype, number of sites of
disease, size of the Institution, age, gender, stage and treat-
ment. These results confirm also in elderly patients the
strong prognostic role of self-assessed quality of life in
patients with advanced lung cancer [26].
In the last years, several authors have retrospectively ana-
lyzed the outcomes of elderly patients, compared with
those in younger patients, in clinical trials for NSCLC
patients whose eligibility criteria did not have an upper
limit for age. The ECOG 5592 randomised trial compared
three platinum-based chemotherapy regimens for NSCLC
[15]. QOL was assessed by FACT-Lung questionnaire.
Younger and older patients showed similar baseline QOL
scores, with equivalent decline over time in functional
well-being, and showed comparable outcomes in terms of
response rates, toxicity and survival. The authors conclude
that advanced age itself should not preclude standard
NSCLC treatment. However, the concern about worse
compliance to QOL questionnaires by elderly patients
seems to be confirmed in this trial, because only 21.5% of
elderly patients completed the QOL questionnaire admin-
istered after 6 months, compared with 37.2% of younger
patients: the authors themselves recognize that this signif-
icant difference most likely means that the entire popula-
tion of elderly patients was actually worse than suggested
by the data.
Quality of life in elderly patients with breast cancer
Health-related QOL of patients with breast cancer has
been an important topic in clinical research over the last
decades [27]. However, also for this tumor, there are very
few data derived from prospective clinical trials specifi-
cally dedicated to elderly patients, and most of the knowl-
edge on this topic is derived from subgroup analysis of
studies conducted in postmenopausal women. This is dis-
appointing, because a high proportion of newly diag-
nosed breast cancers affect elderly people, and better
scientific evidence on the correct management of these
patients would greatly help the daily clinical practice.
In the survey by Talarico et al [9], addressing the underrep-
resentation of elderly patients in clinical trials, attention
has been dedicated to study the impact on this phenome-
non of the different types of treatments. The authors
found that older women with breast cancer are just as
likely as younger patients to enter studies of hormonal
treatments, which typically have mild side effects, but they
are much less likely to get into studies of chemotherapy,
that is expected to more negatively affect QOL. The con-
siderations that make elderly patients at higher risk of
undertreatment, are no different in the clinical practice
either. An Italian survey [28] on the treatment modalities
of nearly three thousand women affected by breast cancer
with metastatic lymph-nodes, showed that fewer elderly
patients had received standard radiation treatment after
breast conservation, and that adjuvant chemotherapy was
proposed to only 6% of the patients, compared to 35% of
the younger counterpart.
Here again, studies specifically evaluating the safety and
efficacy of different therapies in elderly patients would
give clear answers on what is worth and what is not, and
what is safe and what is not, without leaving the choice to
personal, subjective decisions that may be reasonable but
remain non evidence-based. QOL would probably have
an important role in trials dedicated to each of the steps in
the treatment of elderly patients with breast cancer, from
the choice of the best modality of loco-regional treatmentHealth and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/44
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for early disease to the choice of the best palliative treat-
ment for metastatic patients.
An example of the role of QOL assessment in elderly
patients with early breast cancer comes from a study ded-
icated to breast-conserving treatment [29]. Age itself
should not be a contra-indication for conservative sur-
gery, but retrospective studies have indicated that elderly
patients are less likely to be treated conservatively. The
EORTC 10850 randomised trial analyzed survival and
QOL in elderly patients (>70 years) with early breast can-
cer, undergoing mastectomy or tumour excision plus
tamoxifen. A QOL questionnaire consisting of 36 items,
covering nine different domains, was filled out by 136
patients (65 in the mastectomy arm and 71 in the local
excision arm) during the first year of follow-up. No signif-
icant difference in the duration of survival between the
two treatment arms was observed in the subgroup of
patients included in the QOL sub-study. Patients assigned
to tumour excision and tamoxifen did not differ from
those undergoing mastectomy in terms of fatigue, emo-
tional functioning, fear of recurrence, social support,
physical functioning and leisure time activities. However,
conservatively treated patients reported fewer arm prob-
lems and a borderline significant benefit in body image.
In conclusion, QOL appears somewhat better after con-
servative treatment, and the authors encourage the use of
this approach also in older patients.
The study by Crivellari et al. [30] is an example of the role
of QOL assessment in the evaluation of adjuvant chemo-
therapy. They analyzed the data collected as part of the
International Breast Cancer Study Group Trial VII, in
order to evaluate the risk/benefit ratio of adjuvant chem-
otherapy for postmenopausal women with operable
breast cancer with metastatic axillary lymph-nodes. The
study compared tamoxifen alone for 5 years versus
tamoxifen plus three cycles of classical CMF (cyclophos-
phamide, methotrexate, fluorouracil). QOL was meas-
ured using linear analog self-assessment scales for coping,
physical well-being, mood, and appetite. A higher
number of older women experienced severe toxicity com-
pared with younger patients, but the subjective burdens of
treatment measured by QOL were similar for the two age
groups. This finding was explained by the authors with the
tendency of elderly patients to complain less and endure
symptoms better.
As for advanced disease, there are several reasons to con-
sider QOL assessment of potentially great importance in
elderly patients. Unfortunately, when reviewing literature
on clinical research about this setting of disease to date, it
has been noted that QOL analysis rarely provided
information beyond that obtained from more traditional
medical outcomes, like toxicity [27]. Its use could proba-
bly be recommended in the case that one of the treat-
ments is expected to produce a very mild toxicity, or to
have significantly different side-effects, that could deter-
mine a sensible difference between treatments in terms of
QOL.
Conclusions
There is a need for clinical trials specifically dedicated to
elderly patients, because results are probably more gener-
alizable to clinical pratice than subgroup analysis of stud-
ies without upper age limit. Studies like ECOG 5592 [15],
or the CALGB 9730 [31] have eligibility criteria designed
for adult patients and the enrolled elderly patients just
represent a selected subgroup. These patients probably
carry a better prognosis and higher treatment compliance
than the whole elderly population. Information derived
from this kind of selected patients, particularly in the case
of trials with aggressive and toxic treatment approaches,
can be misleading and dangerous if generalised to clinical
practice [32]. Investigators from the Food and Drug
Administration are encouraging the development of strat-
egies to increase the number of older patients enrolled in
cancer clinical trials [9] and are promoting prospective tri-
als designed specifically for those aged 65 and older.
Quality of Life has become a common endpoint in clinical
research on cancer treatment. Scientific community is
often facing the problem of underrepresentation of eld-
erly patients in clinical trials, and it seems easy to predict
for the near future a growing number of studies dedicated
to elderly patients, probably with a majority of these stud-
ies providing a Quality of Life assessment. As described,
this assessment in the elderly is still complicated by sev-
eral unresolved methodological problems (frequency of
illiteracy, worse compliance with the questionnaires,
influence of concomitant diseases, use of instruments not
specifically validated in the aged population). Therefore,
planning of these trials should be made with caution.
The role of a systematic Quality of Life assessment in clin-
ical practice is very important. Comprehensive assessment
of the elderly cancer patients, also based on self-report
methodology like Quality of Life questionnaires, has been
proven feasible and useful in some settings [33]. Quality
of Life assessment could be useful not only because it has
a strong prognostic power for survival of patients, but also
to allow for the discussion with the patient of the answers
given to specific items of the questionnaire. This discus-
sion may help the clinician to better assess the overall bur-
den of symptoms suffered by the patient and the relative
importance given to each of them, in order to better plan
and modify the best treatment strategy.
In conclusion, some steps have been done in the field of
clinical cancer research dedicated to elderly patients, andHealth and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/44
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the role of Quality of Life assessment in this setting is
promising. However, many methodological problems are
still to be resolved, to allow the best use of these poten-
tially useful instruments. A Quality of Life assessment in
clinical practice seems particularly useful for elderly
patients, allowing better communication between patient
and clinician, and a wider application of properly selected
instruments should be recommended.
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